Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
11 p, 474.2 KB Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease / Socinski, Mark A. (Univeristy of Pittsburgh Cancer Institute) ; Kaye, Frederic J. (University of Florida College of Medicine) ; Spigel, David R. (Sarah Cannon Research Institute) ; Kudrik, Fred J. (South Carolina Oncology Associates) ; Ponce, Santiago (Hospital 12 de Octubre (Madrid)) ; Ellis, Peter M. (Juravinski Cancer Centre) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Lorigan, Paul (University of Manchester/Christie NHS Foundation Trust) ; Gandhi, Leena (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Gutierrez, Martin E. (Holy Cross Hospital) ; Nepert, Dale (Clinical Development. ImmunoGen Inc) ; Corral, Jesus (Hospital 12 de Octubre (Madrid)) ; Ares, Luis Paz (Hospital 12 de Octubre (Madrid)) ; Universitat Autònoma de Barcelona
Lorvotuzumab mertansine (LM, IMGN901) is a CD56-targeting antibody-drug conjugate developed for tumor-selective delivery of the cytotoxic maytansinoid DM1. This phase 1/2 study evaluated the combination of LM with first-line carboplatin/etoposide chemotherapy in patients with extensive-disease small-cell lung cancer. [...]
2017 - 10.1016/j.cllc.2016.09.002
Clinical Lung Cancer, Vol. 18 Núm. 1 (january 2017) , p. 68-76.e2  

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.